Ormeloxifene
This article needs attention from an expert on the subject. See the talk page for details. WikiProject Medicine may be able to help recruit an expert. (November 2008) |
| ||||||||||||||||||||||||||||||||||||
|
Ormeloxifene (also known as Centchroman) is one of the selective estrogen receptor modulators,[1] or SERMs, a class of medication which acts on the estrogen receptor. It is best known as a non-hormonal, non-steroidal oral contraceptive which is taken once per week. In India, ormeloxifene has been available as birth control since the early 1990s, and it is currently marketed there under the trade name Saheli.[2] Ormeloxifene has also been licensed under the trade namesNovex-DS, Centron and Sevista.
Contents
Method of action
Ormeloxifene is a SERM, or selective estrogen receptor modulator. In some parts of the body, its action is estrogenic (e.g, bones), in other parts of the body, its action is anti-estrogenic (e.g., uterus, breasts.[3] It causes an asynchrony in the menstrual cycle between ovulation and the development of the uterine lining, although its exact mode of action is not well defined. In clinical trials, it caused ovulation to occur later than it normally would in some women (Singh 2001), but did not affect ovulation in the majority of women, while causing the lining of the uterus to build more slowly. It speeds the transport of any fertilized egg through the fallopian tubes more quickly than is normal (Singh 2001). Presumably, this combination of effects creates an environment such that if fertilization occurs, implantation will not be possible.[4]
Usage
Ormeloxifene may be used as a contraceptive or as a treatment for dysfunctional uterine bleeding.
As birth control
Ormeloxifene may be used as a weekly oral contraceptive. This is touted as a major advantage by its developer and its manufacturer. Hormonal birth control pills should be taken at approximately the same time each day. In the case of progestogen only pills other than Cerazette that do not consistently inhibit ovulation, a delay of as little as three hours can increase the risk of pregnancy because of the limited duration of their effect on the cervical mucus. Ormeloxifene's weekly schedule is an advantage for women who prefer an oral contraceptive, but find it difficult or impractical to adhere to a daily schedule.
For the first sixteen weeks of use, it is advised to take the ormeloxifene pill twice per week. From the thirteenth week on, it is taken once per week. [5] The consensus is that backup protection in the first month is a cautious but sensible choice. A standard dose is 30mg weekly, but 60mg loading doses can reduce pregnancy rates by 38%. [6]
Other
Ormeloxifene has also been proposed as a treatment for menorrhagia.[7]
Use in treatment of mastalgia and fibroadenoma has also been described.[8]
Effectiveness
One Phase III multicenter trial of ormeloxifene 30 mg weekly by 898 women for an average of 15 months found a method failure Pearl Index of 2.84.[9]
A second Phase III multicenter trial of ormeloxifene 30 mg twice-a-week for 3 months followed by 30 mg weekly by 376 women for an average of 10.5 months found a method failure Pearl Index of 1.83 and a 12-month life-table method failure pregnancy rate of 1.63% ±0.74%.[10]
The overall actual use (method failure plus user failure) Pearl Index was 9 in both Phase III multicenter trials of ormeloxifene — an order of magnitude less effective than found in Phase III multicenter trials of combined oral contraceptive pills.[4]
Manufacture and marketing
Ormeloxifene has been tested and licensed as a form of birth control, as well as a treatment for dysfunctional uterine bleeding. It was first manufactured by Torrent Pharmaceuticals, and marketed as birth control under the trade name Centron. Centron was discontinued. A new license for ormeloxifene was issued to Hindustan Latex Ltd., which now manufactures ormeloxifene as birth control under the trade name Saheli. Torrent Pharmaceuticals has resumed manufacture of ormeloxifene under the trade name Sevista, as a treatment for dysfunctional uterine bleeding.
Synthesis
Ray, Suprabhat; Grover, Payara K.; Kamboj, Ved P.; Setty, B. S.; Kar, Amiya B.; Anand, Nitya (1976). "Antifertility agents. 12. Structure-activity relation of 3,4-diphenylchromenes and -chromans". Journal of Medicinal Chemistry. 19 (2): 276. doi:10.1021/jm00224a014. PMID 1249807.
See also
References
Cite error: Invalid <references>
tag;
parameter "group" is allowed only.
<references />
, or <references group="..." />
External links
- United States National Library of Medicine Ormeloxifene entry in the Medical Subject Headings (MeSH) database
- United States National Library of Medicine Centchroman entry in the Medical Subject Headings (MeSH) database
- Reproductive Health Online, a Johns Hopkins University affiliate providing information on Centchroman
- Saheli manufacturer's website - Product details
- Saheli manufacturer's website - Clinical studies
- Central Drug Research Institute, Lucknow, India: a government-funded laboratory, conducting R&D on Centchroman as birth control.
- Ministry of Health and Family Welfare - Indian government site; information about availability of Saheli.
- ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
- ↑ >">"<< HLL - Product Overview >>".
- ↑ Gara Rishi Kumar, Konwar Rituraj, Bid Hemant K and MM Singh. In-vitro anti-cancer breast activity of ormeloxifene is mediated via induction of apoptosis and autophagy. 37th annual conference of the endocrine society of India. 30 nov-2 dec, 2007. Abstract p35.
- ↑ 4.0 4.1 Singh M (2001). "Centchroman, a selective estrogen receptor modulator, as a contraceptive and for the management of hormone-related clinical disorders". Med Res Rev. 21 (4): 302–47. doi:10.1002/med.1011. PMID 11410933.
- ↑ http://www.reproline.jhu.edu/english/1fp/1advances/old/1centch/ceorvw.htm
- ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
- ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
- ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
- ↑ Puri V; et al. (1988). "Results of multicentric trial of Centchroman". In Dhwan B. N., et al. (eds.). Pharmacology for Health in Asia : Proceedings of Asian Congress of Pharmacology, 15-19 January 1985, New Delhi, India. Ahmedabad: Allied Publishers.
- ↑ Nityanand S; et al. (1990). "Clinical evaluation of Centchroman: a new oral contraceptive". In Puri, Chander P.; Van Look, Paul F. A. (eds.). Hormone Antagonists for Fertility Regulation. Bombay: Indian Society for the Study of Reproduction and Fertility.
- Pages with script errors
- Pages with broken file links
- Miscellaneous articles needing expert attention
- Articles needing expert attention from November 2008
- Articles with invalid date parameter in template
- All articles needing expert attention
- 2Fix
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Hormonal contraception
- Selective estrogen receptor modulators
- Drugs acting on the genito-urinary system
- Pyrrolidines
- Phenol ethers
- Tetralines
- CS1 maint: Explicit use of et al.
- CS1 maint: Extra text: editors list
- CS1 maint: Multiple names: editors list